6th Annual Oncolytic Virotherapy Summit
26-28 Oct 2021
Eurofins Viracor BioPharma will be exhibiting and sponsoring the 6th Annual Oncolytic Virotherapy Summit in Boston, October 26-28th, and we are excited to share our latest comprehensive assay offering for next generation sequencing to enable genomic profiling of tumor samples with PanCancerIQ™.
Eurofins Viracor BioPharma Immunotherapy Force Multiplier
It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.